Full article: Nivolumab in squamous cell carcinoma of the head and neck
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody- Associated Diseases e977 Potential Role of CHI3
Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy | Scientific Reports
The East Carolinian, March 6, 1997 - ECU Digital Collections
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies | Circulation Research
Northern New England Clinical Oncology Society - 2022 Annual Meeting Accepted Abstracts
Frontiers | Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
Diagnostics | Free Full-Text | Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Cancers | Free Full-Text | Comedications with Immune Checkpoint Inhibitors: Involvement of the Microbiota, Impact on Efficacy and Practical Implications
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy - Curry - 2017 - Journal of Cutaneous Pathology - Wiley Online Library
PDF) Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade | Nature Communications
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy | Nature Reviews Clinical Oncology
Unorganized› @ Area 52 (US) - Guild Profile
PDF) A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
Northern New England Clinical Oncology Society - 2022 Annual Meeting Accepted Abstracts
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics | Chemical Reviews
Frontiers | TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
MKA Fall 2019 Review Magazine by Montclair Kimberley Academy - Issuu
Frontiers | The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Northern New England Clinical Oncology Society - 2022 Annual Meeting Accepted Abstracts
Cancers | Free Full-Text | Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
